This confirms what we already knew... As reported today at the European Society of Cardiology in Amsterdam: "Women with AF receive less anticoagulation treatment than men despite the fact that they are at greater risk of stroke. The new CHA2DS2-VASc score should be used more stringently, especially in women, to optimise their treatment. Treatment of …
Read More
EP Lab Digest recently published Gender Matters: Why Afib Is More Fatal for Women, authored by StopAfib.org founder Mellanie True Hills. In it, she discussed the research into why atrial fibrillation and afib-related strokes are more deadly for women and what can be done. Topics include: Stroke and bleeding risk assessment tools, including CHADS2, CHA2DS2-VASc, …
Read More
Set your DVRs, or watch live, on Saturday, March 23, at 8AM ET/PT, as the Discovery Channel unveils the atrial fibrillation documentary, “A Heartbeat Away From Stroke”. StopAfib.org was thrilled to collaborate with Discovery Channel and other organizations on this documentary. Learn more at StopAfib.org Collaborates on Discovery Channel Atrial Fibrillation Documentary
Read More
There is interesting new information in an article today regarding the Pope's atrial fibrillation and strokes. It reports that he had a bleeding stroke in 1991, along with a stroke in 2005. The bleeding stroke could certainly explain why he was refusing anticoagulants. Even more interestingly, the article also reports that he had a pacemaker …
Read More
Press Release: Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban) Friday, December 28, 2012 5:46 pm EST PRINCETON, N.J. & NEW YORK--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved ELIQUIS® (apixaban). Please see full Prescribing Information including BOXED WARNING and Medication Guide …
Read More
StopAfib.org is pleased to unveil the Top Ten Atrial Fibrillation Videos of 2012. This year the FIRM ablation interviews with Dr. Narayan topped the list. Other popular topics included stroke prevention, new afib guidelines, sleep apnea, and medications. Stories about efficacy of catheter ablation and surgical procedures, comparisons of rate and rhythm control, and other …
Read More
Good to see the FDA moving on this as we're starting to hear of afib patients with mechanical heart valves getting Pradaxa. Here is the FDA announcement... ISSUE: The U.S. Food and Drug Administration (FDA) is informing health care professionals and the public that the blood thinner (anticoagulant) Pradaxa (dabigatran etexilate mesylate) should not be used …
Read More
StopAfib.org is pleased to unveil the Top Ten Atrial Fibrillation Articles of 2012. There were many topics of interest this year to the atrial fibrillation patient community. As always, the top interest was atrial fibrillation stroke prevention — that included the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for anticoagulants, the HAS-BLED tool …
Read More
Patients with atrial fibrillation are at higher risk of suffering stroke and other complications related to the development of blood clots in their heart. Until 2010, the only oral anticoagulant (blood thinner) to prevent strokes in Afib was warfarin (Coumadin®). Now there are two new oral anticoagulants available in the United States--dabigatran (Pradaxa®) and rivaroxaban …
Read More
The Alliance for Aging Research and the AFib Optimal Treatment Task Force have released a new survey that found that atrial fibrillation patients are active in the decision-making process regarding their treatment. Learn more and access the survey reports at: Alliance for Aging Research Releases Survey of AFib Patients 65+ that Finds Active Participation in …
Read More